...

Publications - Impact Factor Journals 2022

[4] WOLRAB, D., R. JIRASKO, E. CIFKOVA, M. HORING, D. MEI, M. CHOCHOLOUSKOVA, O. PETERKA, J. IDOWIAK, T. HRNCIAROVA, L. KUCHAR, R. AHRENDS, R. BRUMAROVÁ, D. FRIEDECKÝ, G. VIVO-TRUYOLS, P. SKRHA, J. SKRHA, R. KUCERA, B. MELICHAR, G. LIEBISCH, R. BURKHARDT, M. WENK, A. CAZENAVE-GASSIOT, P. KARASEK, I. NOVOTNY, K. GREPLOVA, R. HRSTKA a M. HOLCAPEK. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nature Communications. 2022, 13 (1), 124. ISSN: 2041-1723. IF: 14.919. PMID: 35013261
[3] ORTEGA, A., I. VERA, M. DÍAZ, C. NAVARRO, M. ROJAS, W. TORRES, H. PARRA, J. SALAZAR, J. DE SANCTIS a V. BERMUDEZ. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises. Molecular Sciences. 2022, 2022 (23), 430. ISSN: 1422-0067. IF: 5.924. PMID: 35008857
[2] HRUŠKA, M. a D. HOLUB. Evaluation of an integrative Bayesian peptide detection approach on a combinatorial peptide library. European Journal of Mass Spectrometry. 2022, - -. ISSN: 1469-0667. IF: 1.067. PMID: 34989269
[1] HRUBÁ, L., P. POLISHCHUK, V. DAS, M. HAJDÚCH a P. DŽUBÁK. An identification of MARK inhibitors using high throughput MALDI-TOF mass spectrometry. Biomedicine & Pharmacotherapy. 2022, - -. ISSN: 0753-3322. IF: 6.530. PMID: 34923338